|Articles|June 1, 2001

June 2001
Volume 7
Issue 6

Does the HEDIS Asthma Measure Go Far Enough?

Author(s)James H. Glauber, MD, MPH

Download PDF: Does the HEDIS Asthma Measure Go Far Enough?

Articles in this issue

about 25 years ago

Article

Health Plan's Use of Asthma Quality Improvement Projects to Meet NCQA Accreditation Standards

about 25 years ago

Article

Diagnosis and Care of Irritable Bowel Syndrome in a Community-Based Population

about 25 years ago

Article

Prevalence and Determinants of Osteoporosis Drug Prescription Among Patients with High Exposure to Glucocorticoid Drugs

about 25 years ago

Article

Effect of Rofecoxib Therapy on Measures of Health-Related Quality of Life in Patients with Osteoarthritis

about 25 years ago

Article

Rheumatoid Arthritis: Guidelines for Emerging Therapies

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

State Medicaid Budgetary Implications of New Cancers

ByAmanda C. Chen, PhD,Anuraag R. Kansal, PhD,David C. Grabowski, PhD

July 2nd 2026

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

ByKaitlyn T. Haas, PharmD,Joseph J. Saseen, PharmD, BCPS, BCACP,Oliver Titus, MS,Nathan Lamberton, PharmD, BCACP,Lisa M. Schilling, MD, MSPH,Keri N. Hogan, PharmD, BCACP,Alison Marks, BA,Sarah J. Billups, PharmD, BCPS

July 1st 2026

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Does the HEDIS Asthma Measure Go Far Enough?

Articles in this issue

Related Content

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Trending on AJMC

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Does the HEDIS Asthma Measure Go Far Enough?

Articles in this issue

Related Content

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Trending on AJMC

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer